ARTICLE
28 February 2018

Health Canada Publishes Updated Guidance Document On Classification Of Products At The Device-Drug Interface

SB
Smart & Biggar
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
On February 7, 2018, Health Canada published an update to the guidance document Classification of Products at the (Medical) Device-Drug Interface.
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On February 7, 2018, Health Canada published an update to the guidance document Classification of Products at the (Medical) Device-Drug Interface. According to Health Canada's notice, the update is "intended to reflect the changes to the definition of (medical) device made to the Food and Drugs Act (the Act) following the enactment of the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) on November 6, 2014, and to bring greater clarity to the description of how Health Canada classifies health products at the device-drug interface."

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

ARTICLE
28 February 2018

Health Canada Publishes Updated Guidance Document On Classification Of Products At The Device-Drug Interface

Canada Food, Drugs, Healthcare, Life Sciences
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More